clinical trial · NCT04225871
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·active not recruiting·n = 200
Generalized Myasthenia Graviszilucoplan (RA101495)
brief summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
started
Dec 23, 2019
primary completion
Jun 2, 2026
completion
Jun 2, 2026
last updated
Apr 24, 2026
official title
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol